India Archives - Page 2 of 3

Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk).

Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.

From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

2021

M72/AS01e

Hypothetical vaccines, M72/AS01e

Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.

Estimating the epidemiologic impact of new TB vaccines in high-burden settings

2022-2027

Ongoing

This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.

Demand insights for uptake of TB vaccine

2022

Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state

Is neglect of self-clearance biasing TB vaccine impact estimates?

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report

2024

A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.

Acceptability and effect on public and cost-effectiveness impact

BCG revaccination, M72/AS01e

Ongoing

Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study